National Coverage Analysis (NCA)

Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration

CAG-00066R3

Expand All | Collapse All

Contacts

Kim Long
Kimberly.Long@cms.hhs.gov
410-786-5702
Lead Analysts
Lead Medical Officers

History of Considerations

History Title ID
Original Consideration Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration CAG-00066N View
First reconsideration Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration CAG-00066R View
Second reconsideration Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration CAG-00066R2 View
Third reconsideration Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration CAG-00066R3 You are here
Fourth reconsideration Ocular Photodynamic Therapy (OPT) with Verteporfin for Macular Degeneration CAG-00066R4 View